Cite
HARVARD Citation
Smolen, J. et al. (2015). Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients. Arthritis research & therapy. 17 (1), pp. 1-15. [Online].